Back to search results

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Abroad (travel likely)RecruitingPHASE2

Conditions

Type 1 Diabetes Mellitus

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Investigational Site Number : 3920015, Ichikawa, Chiba, Japan

  • Investigational Site Number : 3920006, Sapporo, Hokkaido, Japan

  • Investigational Site Number : 3920018, Kobe, Hyōgo, Japan

  • Investigational Site Number : 3920007, Yahaba, Iwate, Japan

  • Investigational Site Number : 3920019, Yokohama, Kanagawa, Japan

  • Investigational Site Number : 3920001, Iruma, Saitama, Japan

  • Investigational Site Number : 3920010, Chūō, Yamanashi, Japan

  • Investigational Site Number : 3920017, Fukuoka, Japan

  • Investigational Site Number : 3920016, Kyoto, Japan

  • Investigational Site Number : 3920004, Osaka, Japan

  • Investigational Site Number : 3920020, Tokyo, Japan

View source on ClinicalTrials.gov(opens in a new tab)